Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial. A targeted treatment that includes Braftovi ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...

A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...